Abstract
Recent works have demonstrated a rare functional variant (R47H) in triggering receptor expressed on myeloid cells (TREM) 2 gene, encoding TREM2 protein, increase susceptibility to late-onset Alzheimer’s disease (AD), with an odds ratio similar to that of the apolipoprotein E ε4 allele. The reduced function of TREM2 was speculated to be the main cause in the pathogenic effects of this risk variant, and TREM2 is highly expressed in white matter, as well as in the hippocampus and neocortex, which is partly consistent with the pathological features reported in AD brain, indicating the possible involvement of TREM2 in AD pathogenesis. Emerging evidence has demonstrated that TREM2 could suppress inflammatory response by repression of microglia-mediated cytokine production and secretion, which may prevent inflammation-induced bystander damage of neurons. TREM2 also participates in the regulation of phagocytic pathways that are responsible for the removal of neuronal debris. In this article, we review the recent epidemiological findings of TREM2 that related with late-onset AD and speculate the possible roles of TREM2 in progression of this disease. Based on the potential protective actions of TREM2 in AD pathogenesis, targeting TREM2 might provide new opportunities for AD treatment.
Similar content being viewed by others
References
Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297(5580):353–356. doi:10.1126/science.1072994
Prinz M, Priller J, Sisodia SS, Ransohoff RM (2011) Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat Neurosci 14(10):1227–1235. doi:10.1038/nn.2923
Streit WJ, Mrak RE, Griffin WS (2004) Microglia and neuroinflammation: a pathological perspective. J Neuroinflammation 1(1):14. doi:10.1186/1742-2094-1-14
Jones B (2012) Alzheimer disease: TREM2 linked to late-onset AD. Nat Rev Neurol 9(1):5. doi:10.1038/nrneurol.2012.254
Niemitz E (2012) TREM2 and Alzheimer’s disease. Nat Genet 45(1):11. doi:10.1038/ng.2513
Neumann H, Daly MJ (2013) Variant TREM2 as risk factor for Alzheimer’s disease. N Engl J Med 368(2):182–184. doi:10.1056/NEJMe1213157
Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E et al (2013) TREM2 variants in Alzheimer’s disease. N Engl J Med 368(2):117–127. doi:10.1056/NEJMoa1211851
Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J et al (2013) Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med 368(2):107–116. doi:10.1056/NEJMoa1211103
Colonna M (2003) TREMs in the immune system and beyond. Nat Rev Immunol 3(6):445–453. doi:10.1038/nri1106
Bouchon A, Dietrich J, Colonna M (2000) Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 164(10):4991–4995
Bouchon A, Hernandez-Munain C, Cella M, Colonna M (2001) A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J Exp Med 194(8):1111–1122
N’Diaye EN, Branda CS, Branda SS, Nevarez L, Colonna M, Lowell C et al (2009) TREM-2 (triggering receptor expressed on myeloid cells 2) is a phagocytic receptor for bacteria. J Cell Biol 184(2):215–223. doi:10.1083/jcb.200808080
Stefano L, Racchetti G, Bianco F, Passini N, Gupta RS, Panina Bordignon P et al (2009) The surface-exposed chaperone, Hsp60, is an agonist of the microglial TREM2 receptor. J Neurochem 110(1):284–294. doi:10.1111/j.1471-4159.2009.06130.x
Ito H, Hamerman JA (2012) TREM-2, triggering receptor expressed on myeloid cell-2, negatively regulates TLR responses in dendritic cells. Eur J Immunol 42(1):176–185. doi:10.1002/eji.201141679
Hsieh CL, Koike M, Spusta SC, Niemi EC, Yenari M, Nakamura MC et al (2009) A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem 109(4):1144–1156. doi:10.1111/j.1471-4159.2009.06042.x
Bajramovic JJ (2011) Regulation of innate immune responses in the central nervous system. CNS Neurol Disord Drug Targets 10(1):4–24
Sun GY, Guan CX, Zhou Y, Liu YP, Li SF, Zhou HF et al (2011) Vasoactive intestinal peptide re-balances TREM-1/TREM-2 ratio in acute lung injury. Regul Pept 167(1):56–64. doi:10.1016/j.regpep.2010.11.008
Takahashi K, Rochford CD, Neumann H (2005) Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med 201(4):647–657. doi:10.1084/jem.20041611
Fenoglio C, Galimberti D, Piccio L, Scalabrini D, Panina P, Buonsanti C et al (2007) Absence of TREM2 polymorphisms in patients with Alzheimer’s disease and Frontotemporal Lobar Degeneration. Neurosci Lett 411(2):133–137. doi:10.1016/j.neulet.2006.10.029
Guerreiro RJ, Lohmann E, Bras JM, Gibbs JR, Rohrer JD, Gurunlian N, et al (2012) Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. Arch Neurol :1–7. doi:10.1001/archneurol.2013.579
Frank S, Burbach GJ, Bonin M, Walter M, Streit W, Bechmann I et al (2008) TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia 56(13):1438–1447. doi:10.1002/glia.20710
Melchior B, Garcia AE, Hsiung BK, Lo KM, Doose JM, Thrash JC et al (2010) Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer’s disease. ASN Neuro 2(3):e00037. doi:10.1042/AN20100010
Bianchin MM, Lima JE, Natel J, Sakamoto AC (2006) The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2. Neurology 66(4):615–616. doi:10.1212/01.wnl.0000216105.11788.0f, author reply −6
Verloes A, Maquet P, Sadzot B, Vivario M, Thiry A, Franck G (1997) Nasu–Hakola syndrome: polycystic lipomembranous osteodysplasia with sclerosing leucoencephalopathy and presenile dementia. J Med Genet 34(9):753–757
Hakola HP (1972) Neuropsychiatric and genetic aspects of a new hereditary disease characterized by progressive dementia and lipomembranous polycystic osteodysplasia. Acta Psychiatr Scand Suppl 232:1–173
Madry H, Prudlo J, Grgic A, Freyschmidt J (2007) Nasu–Hakola disease (PLOSL): report of five cases and review of the literature. Clin Orthop Relat Res 454:262–269. doi:10.1097/01.blo.0000229364.57985.df
Chouery E, Delague V, Bergougnoux A, Koussa S, Serre JL, Megarbane A (2008) Mutations in TREM2 lead to pure early-onset dementia without bone cysts. Hum Mutat 29(9):E194–E204. doi:10.1002/humu.20836
Montalbetti L, Ratti MT, Greco B, Aprile C, Moglia A, Soragna D (2005) Neuropsychological tests and functional nuclear neuroimaging provide evidence of subclinical impairment in Nasu–Hakola disease heterozygotes. Funct Neurol 20(2):71–75
Sessa G, Podini P, Mariani M, Meroni A, Spreafico R, Sinigaglia F et al (2004) Distribution and signaling of TREM2/DAP12, the receptor system mutated in human polycystic lipomembraneous osteodysplasia with sclerosing leukoencephalopathy dementia. Eur J Neurosci 20(10):2617–2628. doi:10.1111/j.1460-9568.2004.03729.x
Thrash JC, Torbett BE, Carson MJ (2009) Developmental regulation of TREM2 and DAP12 expression in the murine CNS: implications for Nasu–Hakola disease. Neurochem Res 34(1):38–45. doi:10.1007/s11064-008-9657-1
Vom Berg J, Prokop S, Miller KR, Obst J, Kalin RE, Lopategui-Cabezas I et al (2012) Inhibition of IL-12/IL-23 signaling reduces Alzheimer’s disease-like pathology and cognitive decline. Nat Med 18(12):1812–1819. doi:10.1038/nm.2965
Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A et al (2012) NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature. doi:10.1038/nature11729
Varnum MM, Ikezu T (2012) The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer’s disease brain. Arch Immunol Ther Exp 60(4):251–266. doi:10.1007/s00005-012-0181-2
Hamerman JA, Jarjoura JR, Humphrey MB, Nakamura MC, Seaman WE, Lanier LL (2006) Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J Immunol 177(4):2051–2055
Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L et al (2006) Cutting edge: TREM-2 attenuates macrophage activation. J Immunol 177(6):3520–3524
Hamerman JA, Tchao NK, Lowell CA, Lanier LL (2005) Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12. Nat Immunol 6(6):579–586. doi:10.1038/ni1204
Takahashi K, Prinz M, Stagi M, Chechneva O, Neumann H (2007) TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis. PLoS Med 4(4):e124. doi:10.1371/journal.pmed.0040124
Piccio L, Buonsanti C, Mariani M, Cella M, Gilfillan S, Cross AH et al (2007) Blockade of TREM-2 exacerbates experimental autoimmune encephalomyelitis. Eur J Immunol 37(5):1290–1301. doi:10.1002/eji.200636837
Singaraja RR (2013) TREM2: a new risk factor for Alzheimer’s Disease. Clin Genet. doi:10.1111/cge.12108
Acknowledgments
This work was supported by grants from the National Natural Science Foundation of China (81000544, 81171209), the Shandong Provincial Natural Science Foundation, China (ZR2010HQ004, ZR2011HZ001), and the Shandong Provincial Outstanding Medical Academic Professional Program.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Jiang, T., Yu, JT., Zhu, XC. et al. TREM2 in Alzheimer’s disease. Mol Neurobiol 48, 180–185 (2013). https://doi.org/10.1007/s12035-013-8424-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-013-8424-8